{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:07:29Z","timestamp":1768352849004,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2002]]},"DOI":"10.1007\/s101560200019","type":"journal-article","created":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T11:07:24Z","timestamp":1387537644000},"page":"115-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species"],"prefix":"10.1016","volume":"8","author":[{"given":"Naoyuki","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fukano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Niki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiharu","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s101560200019_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02348753","article-title":"In vitro and in vivo activities of sparfloxacin and reference drugs against Chlamydia pneumoniae","volume":"1","author":"Soejima","year":"1995","journal-title":"J Infect Chemother"},{"key":"10.1007\/s101560200019_bib0010","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1128\/AAC.41.6.1331","article-title":"In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp","volume":"41","author":"Miyashita","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560200019_bib0015","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/AAC.45.11.3270-3272.2001","article-title":"In vitro and in vivo activity of sitafloxacin against Chlamydia spp","volume":"45","author":"Miyashita","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560200019_bib0020","first-page":"148","article-title":"Clinical study on sparfloxacin in the treatment of chlamydial respiratory infections (in Japanese)","volume":"44","author":"Soejima","year":"1996","journal-title":"Jpn J Chemother"},{"key":"10.1007\/s101560200019_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/AAC.41.1.101","article-title":"In vitro activitiy of BAY 12-8039, a new fluoroquinolone","volume":"41","author":"Woodcock","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560200019_bib0030","first-page":"418","article-title":"Morphological analysis of Chlamydia pneumoniae","volume":"38","author":"Miyashita","year":"1993","journal-title":"Jpn J Chemother"},{"key":"10.1007\/s101560200019_bib0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/jac\/43.6.825","article-title":"Comparative in-vitro activitiy of moxifloxacin, minocycline and azithromycin against Chlamydia spp","volume":"43","author":"Donati","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s101560200019_bib0040","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1128\/AAC.42.4.951","article-title":"In vitro activitiy of a new 8- methoxyquinolone BAY 12-8039, against Chlamydia pneumoniae","volume":"42","author":"Roblin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560200019_bib0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/0002-9343(90)90212-V","article-title":"Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections","volume":"89","author":"Lipsky","year":"1990","journal-title":"Am J Med"},{"key":"10.1007\/s101560200019_bib0050","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1128\/AAC.40.5.1175","article-title":"Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization","volume":"40","author":"Plouffe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560200019_bib0055","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"A multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia","volume":"41","author":"File","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560200019_bib0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/BF01691579","article-title":"Trovafloxacin versus amoxicillin\/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis","volume":"17","author":"Leophonate","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1007\/s101560200019_bib0065","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1128\/AAC.44.5.1409-1409.2000","article-title":"Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae","volume":"44","author":"Hammerschlag","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560200019_bib0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/rmed.1999.0710","article-title":"Community Acquired Pneumonia Study Group. Efficacy and safety of 10 day moxifloxacin 400mg once daily in the treatment of patients with community-acquired pneumonia","volume":"94","author":"Patel","year":"2000","journal-title":"Respir Med"},{"key":"10.1007\/s101560200019_bib0075","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0924-8579(00)00157-6","article-title":"Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae","volume":"15","author":"Hammerschlag","year":"2000","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X02712440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X02712440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s101560200019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:43:04Z","timestamp":1761158584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X02712440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002]]}},"alternative-id":["S1341321X02712440"],"URL":"https:\/\/doi.org\/10.1007\/s101560200019","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2002]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s101560200019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}